News
Important Only
Food ingredients maker Sensient beats Q2 profit view, misses revenue estimates
OverviewSensient Q2 revenue rises 2.7% but misses analyst expectations, per LSEG dataFood ingredients maker's adjusted EPS for Q2 beats consensus, rising 20.8% yr/yrOperating income increases 16.2% to $57.7 mln, driven by Color Group growthOutlookSensient expects 2025 diluted EPS between $3.13 a...Reuters
Fri, Jul 25
UK's CMA Decides That Kpler/Spire Global Merger Does Not Qualify For Investigation
July 25 (Reuters) - UK's CMA:UK'S CMA: MADE REVOCATION ORDER IN RELATION TO COMPLETED ACQUISITION BY KPLER HOLDING SA OF SPIRE GLOBAL INC.'S MARITIME DATA BUSINESSUK'S CMA: DECIDED THAT KPLER/SPIRE GLOBAL MERGER DOES NOT QUALIFY FOR INVESTIGATIONReuters
Fri, Jul 25
Meta Beginning In October, Meta To No Longer Allow Political, Electoral And Social Issue ADS Our Platforms In The EU - Website
July 25 (Reuters) - Meta Platforms Inc META.O:META: BEGINNING IN OCTOBER, META TO NO LONGER ALLOW POLITICAL, ELECTORAL AND SOCIAL ISSUE ADS OUR PLATFORMS IN THE EU - WEBSITESource text: [ID:]Reuters
Fri, Jul 25
Lakeland Financial Reports Record Second Quarter Performance Net Income Grows By 20% To $27.0 Million, As Net Interest Income Expands By 14%
July 25 (Reuters) - Lakeland Financial Corp LKFN.O:LAKELAND FINANCIAL REPORTS RECORD SECOND QUARTER PERFORMANCE; NET INCOME GROWS BY 20% TO $27.0 MILLION, AS NET INTEREST INCOME EXPANDS BY 14%Reuters
Fri, Jul 25
SOBI Announces U.S. Food And Drug Administration Approves Doptelet For The Treatment Of Thrombocytopenia In Pediatric Patients One Year And Older With Persistent Or Chronic Immune Thrombocytopenia
July 25 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:SOBI ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVES DOPTELET® (AVATROMBOPAG) FOR THE TREATMENT OF THROMBOCYTOPENIA IN PEDIATRIC PATIENTS ONE YEAR AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)Reuters
Fri, Jul 25
Castle Biosciences’ Founder, President And CEO Derek Maetzold Named A Most Admired CEO By The Houston Business Journal
July 25 (Reuters) - Castle Biosciences Inc CSTL.O:CASTLE BIOSCIENCES’ FOUNDER, PRESIDENT AND CEO DEREK MAETZOLD NAMED A MOST ADMIRED CEO BY THE HOUSTON BUSINESS JOURNALReuters
Fri, Jul 25
Meta to halt political advertising in EU from October, blames EU rules
By Foo Yun Chee BRUSSELS, July 25 (Reuters) - Meta Platforms META.O will end political, electoral, social issue advertising on its platform in the European Union in early October because of the legal uncertainties due to EU rules targeting political advertising, the U.S. social media company said...Reuters
Fri, Jul 25
Tesla beats Chinese rivals in some driving assisted tests, say China state media, Bytedance
Tesla scores best in Chinese highway test of assisted drivingChinese rivals Xiaomi, Huawei and BYD lag behind in the testMusk reposted "the top results"Chinese brands urged to face up to gap BEIJING, July 25 (Reuters) - Billionaire Elon Musk's Tesla TSLA.O outperformed Chinese riv...Reuters
Fri, Jul 25
Cristian Massacesi, M.D., Joins Bristol Myers Squibb As Executive Vice President, Chief Medical Officer And Head Of Development
July 25 (Reuters) - Bristol-Myers Squibb Co BMY.N:CRISTIAN MASSACESI, M.D., JOINS BRISTOL MYERS SQUIBB AS EXECUTIVE VICE PRESIDENT, CHIEF MEDICAL OFFICER AND HEAD OF DEVELOPMENTReuters
Fri, Jul 25
Morning News Call - U.S., July 25
To access a PDF version of this newsletter, please click here You can read Morning News Call -- US via TOPNEWS U.S. Companies page.If you would like to receive this newsletter through your email, please register at:https://solutions.lseg.com/MorningNewsCallEN-subscription-page For Morning Ne...Reuters
Fri, Jul 25
CBRE Group Inc expected to post earnings of $1.07 a share - Earnings Preview
CBRE Group Inc CBRE.N, CBRE.K is expected to show a rise in quarterly revenue when it reports results on July 29 for the period ending June 30 2025The Dallas Texas-based company is expected to report a 12.7% increase in revenue to $9.454 billion from $8.39 billion a year ago, according to the mea...Reuters
Fri, Jul 25
EMA's CHMP Recommended Not Granting A Marketing Authorisation For Elevidys For Treatment Of Duchenne Muscular Dystrophy
July 25 (Reuters) - EMA'S CHMP: RECOMMENDED NOT GRANTING A MARKETING AUTHORISATION FOR ELEVIDYS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYEMA'S CHMP: EKTERLY RECEIVED POSITIVE OPINION FROM CHMP FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMAReuters
Fri, Jul 25
